Shruthi Vaidhyanathan

Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Arkadiusz Z. Dudek et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 179 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 167 citations · Full text

Medicine, Oncology, Pharmacology +15

Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases

Shruthi Vaidhyanathan, Rajendar K. Mittapalli, Jann N. Sarkaria et al. · Drug Metabolism and Disposition · 2014 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gautham Gampa, Shruthi Vaidhyanathan, Jann N. Sarkaria et al. · Pharmacological Research · 2017 · 49 citations · Full text

Medicine, Molecular Pharmaceutics, Oncology +17

Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling

Shruthi Vaidhyanathan, Xiaoning Wang, John R. Crison et al. · Journal of Pharmaceutical Sciences · 2018 · 44 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14